Ayurvedic chronic-care chain running Madhavbaug clinics and hospitals for heart-disease, diabetes, BP and obesity reversal, with in-house manufacturing of Ayurvedic medicines and diet kits
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 11 | 11 | 11 | 11 | 11 |
| Reserves | 30 | 45 | 52 | 57 | 77 |
| Borrowings | 0 | 2 | 1 | 1 | 3 |
| Other Liabilities | 14 | 12 | 13 | 14 | 14 |
| Total Liabilities | 55 | 70 | 77 | 82 | 105 |
| AssetsFixed Assets | 21 | 28 | 34 | 34 | 35 |
| CWIP | 2 | 2 | 1 | 0 | 2 |
| Investments | 15 | 18 | 21 | 22 | 40 |
| Other Assets | 17 | 21 | 20 | 26 | 28 |
| Total Assets | 55 | 70 | 77 | 82 | 105 |
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | -1 | 11 | 5 |
| Cash from Investing | 1 | -13 | -10 | -24 |
| Cash from Financing | -1 | 15 | -1 | 17 |
| SummaryCapital Expenditure | — | — | — | — |
| Free Cash Flow | -7 | -12 | 2 | -2 |
| FCF Margin | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (19.1×) and current (13.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 13× exit, ₹205 only delivers your return if you pay ₹138. The price is currently baking in 18% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 13×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 16.87 |
| FY28 | 10.0% | 18.56 |
| FY29 | 10.0% | 20.42 |
| FY30 | 10.0% | 22.46 |
| FY31 | 10.0% | 24.71 |
| FY32 | 8.0% ·fade | 26.68 |
| FY33 | 6.0% ·fade | 28.28 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.